These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Biguanides. Mode of action and role in the up-to-date treatment of diabetes mellitus. Fövényi J Ther Hung; 1971; 19(2):43-8. PubMed ID: 5172874 [No Abstract] [Full Text] [Related]
5. Antidiabetic drugs after the University Group Diabetes Program (UGDP). Karam JH; Matin SB; Forsham PH Annu Rev Pharmacol; 1975; 15():351-66. PubMed ID: 1096790 [No Abstract] [Full Text] [Related]
6. Clinical use of oral hypoglycemic agents. Hagg SA Am J Hosp Pharm; 1976 Sep; 33(9):943-7. PubMed ID: 790951 [TBL] [Abstract][Full Text] [Related]
8. [Oral hypoglycemic agents]. Pupo Ade A AMB Rev Assoc Med Bras; 1986; 32(11-12):202-4. PubMed ID: 3299518 [No Abstract] [Full Text] [Related]
9. [Current concepts of the pancreatic and extrapancreatic mechanisms of the action of peroral hypoglycemic sulfonylurea preparations]. Poltorak VV; Gladkikh AI Probl Endokrinol (Mosk); 1985; 31(2):76-85. PubMed ID: 2859589 [No Abstract] [Full Text] [Related]
10. [Pharmacologic profile of oral antidiabetic agents]. Okubo M; Yamane K; Kohno N Nihon Rinsho; 2002 Sep; 60 Suppl 9():310-6. PubMed ID: 12387011 [No Abstract] [Full Text] [Related]
11. Insulin and oral hypoglycaemic agents. I. Physiological and clinical pharmacological aspects. Breidahl HD; Ennis GC; Martin FI; Stawell JR; Taft P Drugs; 1972; 3(1):79-107. PubMed ID: 4559811 [No Abstract] [Full Text] [Related]
12. [Insulin response and lipid and purine metabolic disorders in protodiabetes: evaluation of the changes induced with hypoglycemic drug treatment]. Baraldi B; Carobbio C; Colloredo Mels G; Cocuzza E; Maestri G; D'Amore V; Angeli G Clin Ter; 1980 Apr; 93(2):193-202. PubMed ID: 7004754 [No Abstract] [Full Text] [Related]
13. [Thyroid function in diabetics treated with sulfonylurea and biguanides]. Kasperska-Czyzykowa T; Czech W; Sawicki Z; Woy-Wojciechowski J; Zuławnik W Pol Arch Med Wewn; 1978 Mar; 59(3):275-83. PubMed ID: 580962 [No Abstract] [Full Text] [Related]
14. [Long term efficacy and tolerance of antidiabetic treatments. New data]. Mirouze J Nouv Presse Med; 1974 Jun; 3(24):1551-4. PubMed ID: 4211493 [No Abstract] [Full Text] [Related]
16. [Mode of action of blood glucose lowering biguanides: clinical aspects]. Mehnert H Acta Diabetol Lat; 1969 Sep; 6 Suppl 1():678-84. PubMed ID: 4906985 [No Abstract] [Full Text] [Related]
17. [Possibilities and limits of oral diabetes therapy]. Bruneder H Wien Med Wochenschr; 1985 Apr; 135(6-7):147-51. PubMed ID: 3890376 [No Abstract] [Full Text] [Related]
18. Oral hypoglycemic agents: the pharmacological basis of their clinical use. Davidoff F R I Med J; 1973 Oct; 56(10):409-14. PubMed ID: 4518221 [No Abstract] [Full Text] [Related]
19. Antihyperglycaemic agents. Drug interactions of clinical importance. Scheen AJ; Lefèbvre PJ Drug Saf; 1995 Jan; 12(1):32-45. PubMed ID: 7741982 [TBL] [Abstract][Full Text] [Related]
20. [Behavior of serum insulin under the influence of glisoxepide with and without butylbiguanide]. Birk W; Petrides P Arzneimittelforschung; 1974 Mar; 24(0):425-9. PubMed ID: 4408033 [No Abstract] [Full Text] [Related] [Next] [New Search]